Πλοήγηση ανά Θέμα "neuroleptic agent"
Αποτελέσματα 1-13 από 13
-
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
(2022)Background: Antipsychotic drugs are the mainstay treatment for schizophrenia, yet they are associated with diverse and potentially dose-related side effects which can reduce quality of life. For this reason, the lowest ... -
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
(2022)Background: In clinical practice, different antipsychotics can be combined in the treatment of people with schizophrenia (polypharmacy). This strategy can aim at increasing efficacy, but might also increase the adverse ... -
Association between Motor Signs and Cognitive Performance in Cognitively Unimpaired Older Adults: A Cross-Sectional Study Using the NACC Database
(2022)Aiming to examine whether specific motor signs are associated with worse performance in specific cognitive domains among cognitively unimpaired (CU) individuals, we performed a cross-sectional analysis of data from the ... -
Clozapine associated with autoimmune reaction, fever and low level cardiotoxicity - a case report
(2017)Background: Clozapine is a second-generation antipsychotic drug used in treatment-resistant schizophrenia. Fever induced by clozapine is a rather frequent side-effect which usually occurs in the first 4 weeks of treatment. ... -
Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
(2008)Background: To compare the costs and effects of paliperidone extended release (ER), a new pharmaceutical treatment for the management of schizophrenia, with the most frequently prescribed oral treatments in Greece (namely ... -
Crocus sativus L. extracts and its constituents crocins and safranal; Potential candidates for schizophrenia treatment?
(2021)Schizophrenia is a chronic mental devastating disease. Current therapy suffers from various limitations including low efficacy and serious side effects. Thus, there is an urgent necessity to develop new antipsychotics with ... -
Drug-induced endocrinopathies and diabetes: A combo-endocrinology overview
(2019)In the currently overwhelming era of polypharmacy, the balance of the dynamic and delicate endocrine system can easily be disturbed by interfering pharmaceutical agents like medications. Drugs can cause endocrine abnormalities ... -
The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials
(2021)Rationale: The current pharmacotherapy of bipolar depression often presents limited efficacy and increased risk for adverse events. N-acetylcysteine (NAC) has been suggested as potentially effective and well-tolerated ... -
Effects of the inducible nitric oxide synthase inhibitor aminoguanidine in two different rat models of schizophrenia
(2016)Several lines evidence indicate that the non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist ketamine and the mixed dopamine (DA) D1/D2 receptor agonist apomorphine induce schizophrenia-like symptoms in rodents, ... -
Genetic polymorphism of canine cytochrome P450 2D25 gene
(2004)Human CYP2D6 is involved in the metabolism of a number of drugs including neuroleptics, tricyclic antidepressants, β-adrenoreceptors antagonists and antiarrhythmic drugs. The corresponding canine CYP2D15 have shown similar ... -
The nitric oxide (No) donor sodium nitroprusside (snp) and its potential for the schizophrenia therapy: Lights and shadows
(2021)Schizophrenia is a severe psychiatric disorder affecting up to 1% of the worldwide popula-tion. Available therapy presents different limits comprising lack of efficiency in attenuating negative symptoms and cognitive ... -
The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis
(2022)Background: As comparatively few trials in subgroups of patients with schizophrenia have been done, clinicians need to know whether they can rely on the results of randomised controlled trials (RCTs) in the general population ... -
The role of nitric oxide synthase inhibitors in schizophrenia
(2016)Close to 1% of the world population suffer from schizophrenia. Current medications for this chronic mental disorder have greatly improved treatment over the last half century or more, but, the newer atypical antipsychotics ...